Rocco G. Gogliotti, Dr., Ph.D.

Research Assistant Professor

rocco.gogliotti@vanderbilt.edu
Faculty Appointments
Research Assistant Professor of Pharmacology
Education
Certificate, College Education, Vanderbilt University, Nashville, TennesseePh.D., Biomedical Research, Northwestern University, Evanston/Chicago, IllinoisB.S., Biology, Eastern Michigan University, Ypsilanti, Michigan
Research Description
Rocco Gogliotti joined the VCNDD and the Department of Pharmacology in April of 2012. His research focus is pediatric diseases of the nervous system, and how integration of human samples early in study design can improve the translation success of preclinical discovery efforts. Through a combination of genetic, behavioral and pharmacological methodologies, he seeks to better understand the disparities in nervous system function during health and disease, and to design novel intervention strategies to correct these deficits. Rocco’s work in the VNCDD has focused on the syndromic forms of autism, such as Rett syndrome and MECP2-Duplication syndrome, and the role that metabotropic glutamate receptors and muscarinic acetylcholine receptors play in disease etiology. These studies are rooted in expression data from the brains of human patients, where he has established that mGlu5, mGlu7 and M4 protein levels are significantly reduced. Using novel compounds developed in the VCNDD, he has defined which aspects of neurotransmission are affected by receptor deficiency, and identified specific symptom domains that can be rescued by normalizing their signaling pathways in model mice. The goal of these bench-to-bedside studies is to identify novel components of the basic science underlying disease, which are present in human patients and can be targeted therapeutically to improve the lives of the patients and families afflicted with these devastating disorders.
Publications
Gogliotti RG, Fisher NM, Stansley BJ, Jones CK, Lindsley CW, Conn PJ, Niswender CM. Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M4 Muscarinic Receptor as a Novel Therapeutic Target. J. Pharmacol. Exp. Ther [print-electronic]. 2018 May; 365(2): 291-300. PMID: 29523700, PMCID: PMC5878667, PII: jpet.117.246991, DOI: 10.1124/jpet.117.246991, ISSN: 1521-0103.

Fisher NM, Gogliotti RG, Vermudez SAD, Stansley BJ, Conn PJ, Niswender CM. Genetic Reduction or Negative Modulation of mGlu7 Does Not Impact Anxiety and Fear Learning Phenotypes in a Mouse Model of MECP2 Duplication Syndrome. ACS Chem Neurosci [print-electronic]. 2017 Dec 12/14/2017; PMID: 29227625, DOI: 10.1021/acschemneuro.7b00414, ISSN: 1948-7193.

Stansley BJ, Fisher NM, Gogliotti RG, Lindsley CW, Conn PJ, Niswender CM. Contextual Fear Extinction Induces Hippocampal Metaplasticity Mediated by Metabotropic Glutamate Receptor 5. Cereb. Cortex [print-electronic]. 2017 Nov 11/9/2017; 1-14. PMID: 29136107, PII: 4608047, DOI: 10.1093/cercor/bhx282, ISSN: 1460-2199.

Abe M, Seto M, Gogliotti RG, Loch MT, Bollinger KA, Chang S, Engelberg EM, Luscombe VB, Harp JM, Bubser M, Engers DW, Jones CK, Rodriguez AL, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW. Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines. ACS Med Chem Lett. 2017 Oct 10/12/2017; 8(10): 1110-5. PMID: 29057060, PMCID: PMC5641958, DOI: 10.1021/acsmedchemlett.7b00317, ISSN: 1948-5875.

Gogliotti RG, Senter RK, Fisher NM, Adams J, Zamorano R, Walker AG, Blobaum AL, Engers DW, Hopkins CR, Daniels JS, Jones CK, Lindsley CW, Xiang Z, Conn PJ, Niswender CM. MGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med. 2017 Aug 8/16/2017; 9(403): PMID: 28814546, PMCID: PMC5654528, PII: 9/403/eaai7459, DOI: 10.1126/scitranslmed.aai7459, ISSN: 1946-6242.

Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG. The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia. J Neuroimmune Pharmacol [print-electronic]. 2016 Jun; 11(2): 231-7. PMID: 26872456, PMCID: PMC4848139, PII: 10.1007/s11481-016-9655-z, DOI: 10.1007/s11481-016-9655-z, ISSN: 1557-1904.

Gogliotti RG, Senter RK, Rook JM, Ghoshal A, Zamorano R, Malosh C, Stauffer SR, Bridges TM, Bartolome JM, Daniels JS, Jones CK, Lindsley CW, Conn PJ, Niswender CM. MGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Hum. Mol. Genet [print-electronic]. 2016 May 5/15/2016; 25(10): 1990-2004. PMID: 26936821, PMCID: PMC5062588, PII: ddw074, DOI: 10.1093/hmg/ddw074, ISSN: 1460-2083.

Gogliotti RG, Conn PJ. Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?. Neuropsychopharmacology. 2016 Jan; 41(1): 376-7. PMID: 26657955, PMCID: PMC4677143, PII: npp2015259, DOI: 10.1038/npp.2015.259, ISSN: 1740-634X.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, DiDonato CJ. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum. Mol. Genet [print-electronic]. 2013 Oct 10/15/2013; 22(20): 4084-101. PMID: 23736298, PMCID: PMC3781638, PII: ddt258, DOI: 10.1093/hmg/ddt258, ISSN: 1460-2083.

Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, Didonato CJ. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J. Neurosci. 2012 Mar 3/14/2012; 32(11): 3818-29. PMID: 22423102, PMCID: PMC3679185, PII: 32/11/3818, DOI: 10.1523/JNEUROSCI.5775-11.2012, ISSN: 1529-2401.

Gogliotti RG, Lutz C, Jorgensen M, Huebsch K, Koh S, Didonato CJ. Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice. Neurobiol. Dis [print-electronic]. 2011 Jul; 43(1): 142-51. PMID: 21396450, PMCID: PMC3679180, PII: S0969-9961(11)00073-8, DOI: 10.1016/j.nbd.2011.03.002, ISSN: 1095-953X.

Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS ONE. 2010 Dec 12/29/2010; 5(12): e15887. PMID: 21249120, PMCID: PMC3012126, DOI: 10.1371/journal.pone.0015887, ISSN: 1932-6203.

Kular RK, Gogliotti RG, Opal P. Cpd-1 null mice display a subtle neurological phenotype. PLoS ONE. 2010 Sep 9/9/2010; 5(9): PMID: 20844742, PMCID: PMC2936576, DOI: 10.1371/journal.pone.0012649, ISSN: 1932-6203.

Gogliotti RG, Hammond SM, Lutz C, Didonato CJ. Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun [print-electronic]. 2010 Jan 1/1/2010; 391(1): 517-22. PMID: 19961830, PMCID: PMC2814331, PII: S0006-291X(09)02267-0, DOI: 10.1016/j.bbrc.2009.11.090, ISSN: 1090-2104.

Gavrilina TO, McGovern VL, Workman E, Crawford TO, Gogliotti RG, DiDonato CJ, Monani UR, Morris GE, Burghes AH. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum. Mol. Genet [print-electronic]. 2008 Apr 4/15/2008; 17(8): 1063-75. PMID: 18178576, PMCID: PMC2835541, PII: ddm379, DOI: 10.1093/hmg/ddm379, ISSN: 1460-2083.

Heier CR, Gogliotti RG, DiDonato CJ. SMN transcript stability: could modulation of messenger RNA degradation provide a novel therapy for spinal muscular atrophy?. J. Child Neurol. 2007 Aug; 22(8): 1013-8. PMID: 17761657, PII: 22/8/1013, DOI: 10.1177/0883073807305669, ISSN: 0883-0738.

Wang X, Gargalovic P, Wong J, Gu JL, Wu X, Qi H, Wen P, Xi L, Tan B, Gogliotti R, Castellani LW, Chatterjee A, Lusis AJ. Hyplip2, a new gene for combined hyperlipidemia and increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol [print-electronic]. 2004 Oct; 24(10): 1928-34. PMID: 15331434, PII: 01.ATV.0000143385.30354.bb, DOI: 10.1161/01.ATV.0000143385.30354.bb, ISSN: 1524-4636.